Veracyte, Inc. (VCYT) vs GeneDx Holdings Corp. (WGS)
Veracyte, Inc. and GeneDx Holdings Corp. are both Diagnostics & Research companies. Veracyte, Inc. is the larger, with a market value of $3.9B against $2.6B — 1.5× the size. GeneDx Holdings Corp. has negative trailing earnings, so its P/E is not meaningful; Veracyte, Inc. trades at 31.5×. GeneDx Holdings Corp. grew revenue faster over the last twelve months: 25.4% against 17.3%. Veracyte, Inc. has the higher net margin (20.4% vs −23.4%) and the higher return on invested capital (7.32% vs −27.7%). Across the 18 metrics below, Veracyte, Inc. leads on 15 and GeneDx Holdings Corp. on 3.
Valuation
Profitability
| Metric | VCYT | WGS | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 71.71% | 69.37% | 50.89% |
| Operating margin | 18.82% | (20.34%) | (8.57%) |
| Net margin | 20.37% | (23.40%) | (6.37%) |
| Free cash flow margin | 29.54% | (16.68%) | 0.00% |
| Return on equity | 8.77% | (40.80%) | (2.92%) |
| Return on assets | 8.09% | (22.50%) | (6.71%) |
| Return on invested capital | 7.32% | (27.70%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack